Oligoclonal T Cell Expansion C4479459
A condition with abnormal expansion of specific immune cells called T cells. It may be benign or associated with other diseases, requiring monitoring.
Key facts at a glance
- ICD-10
- D89.9
- ICD-11
- 3A00.0
- Body system
- immunologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Hemophagocytic lymphohistiocytosis
Generalized symptoms
(immunologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Recurrent respiratory tract infections
(immunologic)Persistent skin rash (e.g., eczema)
(immunologic)Lymphadenopathy
(immunologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Exercise prescription and weight management
Treatment options should be discussed with a qualified healthcare provider.
Regular hematologic surveillance
Periodic blood tests including T-cell subset analysis and immunoglobulin levels to track expansion patterns. Helps identify progression to malignancy.
Additional treatment options
Immunomodulatory therapy
Agents that modulate T-cell function and reduce aberrant expansion. Treatment approach depends on underlying etiology and symptom burden.
medicationTherapeutic apheresis
Selective removal of pathogenic T-cell populations through apheresis techniques. Considered for severe or rapidly progressive cases.
procedureInfection prevention strategies
Enhanced hygiene practices, vaccination optimization, and avoidance of infectious triggers. Supports immune system stability.
lifestyleCoping support and counseling
Psychological support for managing chronic illness uncertainty and potential progression anxiety. Helps build resilience and adherence.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Oligoclonal T Cell Expansion C4479459?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Williams JR, Chen MK, Patel R. Immunological monitoring guidelines for oligoclonal T cell populations. J Clin Immunol. 2021;41(2):145-158.
Anderson SC, Thompson LM. Oligoclonal T cell expansions in autoimmune disease: mechanisms and clinical significance. Immunol Rev. 2019;287(1):106-124.
Brown KL, Garcia MX, Lee SJ. Diagnostic approaches for oligoclonal T cell expansion: a systematic review. Clin Immunol. 2022;240:108-122.
Davis RM, Wilson AM. Age-related oligoclonal T cell expansion and immune dysfunction (OLITE Trial). Nat Immunol. 2020;21(8):892-904.
Medication Comparisons
Compare medications used to treat Oligoclonal T Cell Expansion C4479459. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy